3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Recurrence
2
Prostatic Neoplasms
1
Myofibroma
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Leiomyoma
1
Insulin Resistance
1
Endometriosis
1
Dementia
1
Cognitive Dysfunction
1
Alzheimer Disease
1
Interventions
Dexamethasone
45
Bortezomib
19
Lenalidomide
18
Calcium Dobesilate
18
Melphalan
16
Cyclophosphamide
11
pomalidomide
10
daratumumab
9
elotuzumab
8
carfilzomib
8
pembrolizumab
6
ixazomib
6
fludarabine phosphate
6
dexamethasone acetate
6
fludarabine
5
dexamethasone 21-phosphate
5
Filgrastim
5
venetoclax
4
selinexor
4
auricularum
4
Thalidomide
4
Tacrolimus
4
Peripheral Blood Stem Cell Transplantation
4
Magnetic Resonance Spectroscopy
4
liposomal doxorubicin
3
Whole-Body Irradiation
3
Vorinostat
3
Nivolumab
3
Mycophenolic Acid
3
Leukapheresis
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Multiple Myeloma
×
Tablets
×
Clear all
NCT02756663
2016-11-08
PANORAMA-5
Novartis
Phase 2
Withdrawn